Bangkok, Thailand – March 17, 2025 – Perceptra, a leading healthtech startup specializing in AI-assisted medical image diagnosis, today announced that Inspectra MMG has received Food and Drug Administration (FDA), Thailand approval. This milestone marks a significant advancement in the early detection of breast cancer through AI-enhanced mammography analysis.
Inspectra MMG delivers radiologist-level image analysis in real-time, with a unique strength in identifying abnormalities in mammograms especially for dense breast tissue—making it particularly suited for Asian breast types. Inspectra MMG flags subtle abnormalities and provides quantitative scoring to enable more precise diagnosis.
“FDA approval of Inspectra MMG represents a pivotal moment in our mission to empower people’s health prevention and early detection especially in health check up or cancer screening ,” said Supitchaya Phupisut, CEO of Perceptra. “We support radiologists and breast specialists with AI technology, aiming to contribute to early detection and help them overcome challenges in breast cancer screening, especially for women with dense breast tissue,” added Sasinun Worakriangkrai, VP Business Development and Inspectra MMG product owner.
In Thailand, breast cancer is the most common cancer among women. However, limited screening capacity and dense breast characteristics make abnormality detection even more challenging. To tackle this, Inspectra MMG has been trained on a large-scale dataset of over 400,000 images, with more than 70% from C and D breast compositions. Each case has been validated through ultrasound and pathology, enhancing its ability to support accurate and timely detection.
Learn more about Inspectra MMG: https://perceptra.tech/inspectra-mmg/
